目的观察HBe Ag阳性慢性乙型肝炎(乙肝)行恩替卡韦联合胸腺肽胶囊治疗的疗效。方法选择2011年1月至2013年5月120例HBe Ag阳性慢性乙肝患者作为研究对象。以数字随机法分为观察组和对照组各60例。观察组行恩替卡韦联合胸腺肽胶囊治疗,对照组单用恩替卡韦治疗。比较两组观察指标变化及临床疗效。结果(1)临床疗效:治疗52周后,观察组优45例,良14例,差1例,优良率98.3%;对照组优31例,良16例,差13例,优良率78.3%。两组临床疗效差异有统计学意义(χ2=7.531,P<0.01)。(2)治疗26周后,观察组HBV DNA阴转、HBe Ag阴转以及抗HBe转阳率均明显高于对照组,差异均具有统计学意义(P<0.05,P<0.01)。(3)治疗52周后,观察组HBV DNA阴转率[76.7%vs 55.0%,χ2=6.261,P<0.05],HBe Ag阴转率[50.0%vs 25.0%,χ2=8.000,P<0.01],抗HBe转阳率[45.0%vs 20.0%,χ2=8.547,P<0.01]均高于对照组。结论恩替卡韦联合胸腺肽胶囊治疗HBe Ag阳性慢性乙肝临床疗效优于单用恩替卡韦。 Objective To observe the curative effect of HBeAg-positive chronic hepatitis B (hepatitis B) treated with entecavir and thymosin capsules. Methods From January 2011 to May 2013, 120 HBeAg-positive chronic hepatitis B patients were selected as the research object. Randomly divided into observation group and control group of 60 cases. The observation group was treated with entecavir and thymosin capsule, while the control group was treated with entecavir alone. The changes of the observation indexes and the clinical curative effect were compared between the two groups. Results (1) Clinical curative effect: In the observation group, 45 cases were excellent, 14 good and 1 poor, the excellent and good rate was 98.3% after 52 weeks of treatment; the excellent and good rate was 98.3% in the observation group; There was significant difference in clinical efficacy between the two groups (χ2 = 7.531, P <0.01). (2) After 26 weeks of treatment, the levels of HBV DNA negative conversion, HBe Ag negative conversion and anti-HBe positive conversion rate in the observation group were significantly higher than those in the control group, the differences were statistically significant (P <0.05, P <0.01). (3) After 52 weeks of treatment, the negative rate of HBV DNA in the observation group was 76.7% vs 55.0%, χ2 = 6.261, P <0.05; the negative conversion rate of HBe Ag was 50.0% vs 25.0%, χ2 = 8.000 ], The positive rate of anti-HBe [45.0% vs 20.0%, χ2 = 8.547, P <0.01] were higher than the control group. Conclusion The efficacy of entecavir combined with thymosin capsule in the treatment of HBe Ag-positive chronic hepatitis B is better than that of entecavir alone.